Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study
Sign Up to like & getrecommendations! Published in 2021 at "Diabetologia"
DOI: 10.1007/s00125-021-05508-1
Abstract: Concerns have been raised regarding a potential association of use of the incretin-based drugs dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1)-receptor agonists with risk of cholangiocarcinoma. We examined this association in nationwide data… read more here.
Keywords: dpp4 inhibitors; receptor agonists; cholangiocarcinoma; glp receptor ... See more keywords
DPP4 Inhibitors in the Management of Hospitalized Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Sign Up to like & getrecommendations! Published in 2020 at "Advances in Therapy"
DOI: 10.1007/s12325-020-01434-7
Abstract: We studied the effects of dipeptidyl peptidase 4 (DPP4) inhibitors on glycemic control in non-critically ill patients admitted to hospital. We searched MEDLINE and EMBASE for published studies in English up to July 2019. We… read more here.
Keywords: insulin; patients type; dpp4 inhibitors; randomized clinical ... See more keywords
Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes Therapy"
DOI: 10.1007/s13300-018-0488-z
Abstract: The safety and efficacy of dipeptidyl peptidase-4 (DPP4) inhibitors as monotherapy or in combination with other oral antidiabetic agents or basal insulin are well established. DPP4 inhibitors stimulate glucose-dependent insulin secretion and inhibit glucagon production.… read more here.
Keywords: insulin; dpp4 inhibitors; safety efficacy; type diabetes ... See more keywords
Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes Research and Clinical Practice"
DOI: 10.1016/j.diabres.2020.108444
Abstract: In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not… read more here.
Keywords: dpp4 inhibitors; diabetes prevalence; among covid; covid deaths ... See more keywords
Valvular disease: DPP4 inhibitors to prevent aortic valve calcification
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Cardiology"
DOI: 10.1038/nrcardio.2017.28
Abstract: Prolonged fasting and very low calorie diets are known to extend lifespan and are associated with healthy metabolic ageing in animal models. A study now shows that a fasting-mimicking diet (FMD) is also effective in… read more here.
Keywords: dpp4 inhibitors; disease; valvular disease; blood ... See more keywords
IBD — a potential adverse effect of DDP4 inhibitors in T2DM
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Endocrinology"
DOI: 10.1038/s41574-018-0007-3
Abstract: Dipeptidyl peptidase 4 (DPP4) inhibitors are increasingly being used to treat patients with type 2 diabetes mellitus (T2DM); however, new research suggests that this class of drugs could increase the risk of incident inflammatory bowel… read more here.
Keywords: dpp4; effect ddp4; ibd potential; dpp4 inhibitors ... See more keywords
Dipeptidyl peptidase 4 inhibitors attenuate cardiac ischaemia–reperfusion injury in rats with diabetes mellitus type 2
Sign Up to like & getrecommendations! Published in 2020 at "Clinical and Experimental Pharmacology and Physiology"
DOI: 10.1111/1440-1681.13450
Abstract: The aim of our study was to assess and compare the effects of dipeptidyl peptidase 4 (DPP4) inhibitors, saxagliptin and sitagliptin, on metabolic control of disease and cardiac function in rats with diabetes mellitus type… read more here.
Keywords: dpp4 inhibitors; dipeptidyl peptidase; rats diabetes; reperfusion ... See more keywords
Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-020-0990-2
Abstract: Background Sodium glucose cotransporter 2 (SGLT2) inhibitors have shown greater reductions of cardiovascular event risks than dipeptidyl peptidase-4 (DPP4) inhibitors, whereby possible mechanisms may involve the better pleiotropic effects of SGLT2 inhibitors. However, no published… read more here.
Keywords: sglt2 inhibitors; inhibitor; dpp4 inhibitors; pleiotropic effects ... See more keywords
DDP4 inhibitors as novel agents in improving survival in diabetic patients with CRC and lung cancer: A SEER-Medicare study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e14633
Abstract: e14633 Background: DPP4 is a cell surface protein that is widely expressed on different tissues and can play important role in tumor biology by acting as a tumor suppressor or activator, depending upon the level… read more here.
Keywords: crc lung; survival advantage; lung cancer; cancer ... See more keywords
Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.994944
Abstract: Aims Hyperglucagonemia occurs in the pathogenesis of type 2 diabetes mellitus (T2DM). In this meta-analysis, we summarized the effects of DPP4 inhibitors on glucagon levels in patients with T2DM. Materials and methods Randomized controlled trials… read more here.
Keywords: glucagon level; analysis; type diabetes; dpp4 inhibitors ... See more keywords
Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1084960
Abstract: Recent studies have suggested that dipeptidyl peptidase 4 (DPP4) inhibitors increase the risk of development of bullous pemphigoid (BP), which is the most common autoimmune blistering skin disease; however, the associated mechanisms remain unclear, and… read more here.
Keywords: dipeptidyl peptidase; bullous pemphigoid; mas receptor; dpp4 inhibitors ... See more keywords